Teneligliptin HBr is primarily used in the management of type 2 diabetes mellitus. It functions as a dipeptidyl peptidase-4 (DPP-4) inhibitor, which helps regulate blood glucose levels by enhancing the activity of incretin hormones. These hormones stimulate insulin secretion in response to meals and reduce the production of glucagon, thereby improving glycemic control. It is often prescribed as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic medications like metformin or sulfonylureas. The drug is particularly beneficial for patients who require a more stable and sustained glucose-lowering effect without significant risk of hypoglycemia. Its once- or twice-daily dosing regimen also contributes to better patient compliance. Additionally, it has shown efficacy in elderly patients and those with renal impairment, making it a versatile option in diverse diabetic populations.